BD is rolling out a new monitoring platform equipped with artificial intelligence-powered programs that aim to predict potentially life-threatening changes in the patient’s blood pressure | BD described the HemoSphere Alta as the first major launch from the patient monitoring business it acquired last year from Edwards for $4.2 billion.